Digitalis Reduces HF Events but Not Mortality

Overview

Specify that the meta-analysis is based on three trials: DIG, DIGIT-HF, and DECISION.

Background

Heart failure remains a significant clinical challenge, particularly in patients with reduced ejection fraction. Digitalis glycosides, historically used in heart failure management, have shown mixed results regarding mortality reduction. Understanding their impact on heart failure events is crucial for optimizing treatment strategies.

Data Highlights

Key Findings

• Treatment with digitalis glycosides was associated with a lower risk of worsening heart failure events.
• No reduction in cardiovascular or all-cause mortality was observed in the meta-analysis.
• The primary composite outcome occurred in 41% of patients receiving digitalis glycosides compared to 45% in the placebo group.
• First worsening heart failure events occurred in 26% of patients treated with digitalis glycosides versus 33% in the placebo group.
• Safety findings were generally similar between treatment groups, with no substantial differences in serious adverse events.

Clinical Implications

Digitalis glycosides may be considered for patients with heart failure to reduce the risk of worsening heart failure events, although they do not impact mortality. Clinicians should weigh the benefits of symptom management against the lack of mortality benefit when prescribing these agents.

Conclusion

Rephrase to reflect only the findings of the study without editorial interpretation.

Related Resources & Content

1. Damman K, et al., JAMA, 2026 -- Efficacy and Safety of Digitalis Glycosides in Heart Failure
2. Nature Medicine, 2026 -- Low-dose digoxin in patients with heart failure with reduced or mildly reduced ejection fraction: a randomized controlled trial
3. NEJM, 1997 -- The Effect of Digoxin on Mortality and Morbidity in Patients with Heart Failure
4. Clinical Research in Cardiology — Effectiveness of Implantable Cardioverter-Defibrillators in Diabetic Patients with Heart Failure and Reduced Ejection Fraction
5. Clinical Research in Cardiology — The Importance of Prompt and Personalized Management of Heart Failure: A Call for Integration into Updated Guidelines
6. Drugs - Real World Outcomes — Investigating the Link Between Heart Rate Management and Readmission Rates: A Real-World Study of Patients with Heart Failure and Reduced Ejection Fraction
7. JAMA Network
8. New England Journal of Medicine
9. ACC Expert Consensus for Treatment of HFrEF: Key Points - American College of Cardiology